{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicoxkf35agpomcviwgehe4zmdjtig2rqwvjxn2oqvjgepcrljejye",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mlvv4bydtcp2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigev7rr4tdugw6imwuxwotdzz57eexrs2umgu5m5dapswj5suqneu"
    },
    "mimeType": "image/jpeg",
    "size": 119512
  },
  "path": "/news/2026-05-car-cell-therapy-clinical.html",
  "publishedAt": "2026-05-15T13:40:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The University of Texas MD Anderson Cancer Center and CTMC, a joint venture between UT MD Anderson and Resilience, today announced that the Food and Drug Administration (FDA) has issued a 'safe to proceed' for the Investigational New Drug (IND) application for a novel chimeric antigen receptor (CAR) T cell therapy.",
  "title": "Novel CAR T cell therapy moves into clinical studies"
}